NPY1–36 and PYY1–36 activate cardiac fibroblasts: An effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 9, 2015, Pages H1528-H1542

  Zhu, Xiao ^a   Gillespie, Delbert G ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac fibroblasts; Cell proliferation; Dipeptidyl peptidase 4; Neuropeptide Y1 36; Peptide YY1 36; Receptor for activated C kinase 1; Spontaneously hypertensive rats

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ANGIOTENSIN II; COLLAGEN; DIPEPTIDYL PEPTIDASE IV; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y[3-36]; PEPTIDE YY; PEPTIDE YY [3-36]; PERTUSSIS TOXIN; PHOSPHOLIPASE C; RECEPTOR FOR ACTIVATED C KINASE 1; SHORT HAIRPIN RNA; SITAGLIPTIN; UNCLASSIFIED DRUG; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; BISINDOLYLMALEIMIDE I; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESTRANE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PEPTIDE FRAGMENT; PEPTIDE YY (1-36); PROTEIN KINASE C; RACK1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART FIBROBLAST; HEREDITARY HYPERTENSION; HUMAN; HUMAN CELL; MALE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARDIAC MUSCLE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENETICS; HYPERTENSION; METABOLISM; SIGNAL TRANSDUCTION; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; COLLAGEN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ESTRENES; FIBROBLASTS; GTP-BINDING PROTEINS; HYPERTENSION; INDOLES; MALEIMIDES; MYOCARDIUM; NEUROPEPTIDE Y; PEPTIDE FRAGMENTS; PEPTIDE YY; PERTUSSIS TOXIN; PROTEIN KINASE C; PYRROLIDINONES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION; SITAGLIPTIN PHOSPHATE; TYPE C PHOSPHOLIPASES;

EID: 84946043945     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00070.2015     Document Type: Article

References (59)

1. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagonderived peptides in the rat. Pflügers Arch 438: 299-306, 1999.
2. 3-36: part I. Distribution, release and actions. Obes Surg 16: 651-658, 2006.
3. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60: 1454-1470, 2006.
4. Bauvois B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem J 252: 723- 731, 1988.
5. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 228: 217-244, 2003.
6. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820, 1994.
7. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687, 2005.
8. Chen S, Spiegelberg BD, Lin F, Dell EJ, Hamm HE. Interaction of GβY with RACK1 and other WD40 repeat proteins. J Mol Cell Cardiol 37: 399-406, 2004.
9. Cheng D, Zhu X, Barchiesi F, Gillespie DG, Dubey RK, Jackson EK. Receptor for activated protein kinase C1 regulates cell proliferation by modulating calcium signaling. Hypertension 58: 689-695, 2011.
10. 1-36 in SHR vs. WKY preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol 304: F770-F780, 2013.
11. Chung CC, Hsu RC, Kao YH, Liou JP, Lu YY, Chen YJ. Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-β and angiotensin II signaling. Int J Cardiol 176: 386-393, 2014.
12. Colombo F, Gosselin H, El-Helou V, Calderone A. β-Adrenergic receptor-mediated DNA synthesis in neonatal rat cardiac fibroblasts proceeds via a phosphatidylinositol 3-kinase dependent pathway refractory to the antiproliferative action of cyclic AMP. J Cell Physiol 195: 322-330, 2003.
13. Cowling RT, Yeo SJ, Kim IJ, Park JI, Gu Y, Dalton ND, Peterson KL, Greenberg BH. Discoidin domain receptor 2 germline gene deletion leads to altered heart structure and function in the mouse. Am J Physiol Heart Circ Physiol 307: H773-H781, 2014.
14. 2B receptors. Circulation 96: 2656-2666, 1997.
15. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK. Pancreatic polypeptide- fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension 47: 545-551, 2006.
16. Freire RD, Cardoso MA, Gimeno SG, Ferreira SR; Japanese-Brazilian Diabetes Study Group. Dietary fat is associated with metabolic syndrome in Japanese Brazilians. Diabetes Care 28: 1779-1785, 2005.
17. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflügers Arch 433: 571-579, 1997.
18. Galderisi M. Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient. Am J Hypertens 24: 507-517, 2011.
19. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 108: 277-292, 2005.
20. Gouya G, Voithofer P, Neuhold S, Storka A, Vila G, Pacher R, Wolzt M, Hülsmann M. Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure. Int J Clin Pract 68: 1293-1300, 2014.
21. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR: TECOS. Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232-242, 2015.
22. Hemmeryckx B, Swinnen M, Gallacher DJ, Rong Lu H, Roger Lijnen H. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. Eur J Pharmacol 723: 175-180, 2014.
23. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24: 102-108, 1990.
24. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 60: 757-764, 2012.
25. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 65: 238-249, 2015.
26. 1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 323: 431-437, 2007.
27. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23: 570-578, 1994.
28. Lijnen P. Angiotensin II-induced proliferation of neonatal and adult rat cardiac fibroblasts. Hypertension 51: e50, 2008.
29. Manning S, Batterham RL. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu Rev Physiol 76: 585-608, 2014.
30. Marko L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Muller DN. Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling. Hypertension 64: 1032-1039, 2014.
31. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128: 159-165, 2005.
32. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24, 1999.
33. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall TX 4th. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50: 143-150, 1998.
34. Moran GW, O'Neill C, Padfield P, McLaughlin JT. Dipeptidyl peptidase- 4 expression is reduced in Crohn's disease. Regul Pept 177: 40-45, 2012.
35. Nyquist-Battie C, Cochran PK, Sands SA, Chronwall BM. Development of neuropeptide Y and tyrosine hydroxylase immunoreactive innervation in postnatal rat heart. Peptides 15: 1461-1469, 1994.
36. Olson ER, Shamhart PE, Naugle JE, Meszaros JG. Angiotensin IIinduced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase C and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 51: 704-711, 2008.
37. Qi GM, Jia LX, Li YL, Li HH, Du J. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology 155: 2254-2265, 2014.
38. Savarese G, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol 181: 239- 244, 2015.
39. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 10: 73-84, 2013.
40. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326.
41. Shanks J, Herring N. Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. Am J Physiol Regul Integr Comp Physiol 305: R1411-R1420, 2013.
42. Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ, Herring N. Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 305: H980-H986, 2013.
43. 2 receptors for neuropeptide Y and peptide YY by affinity cross-linking. J Biol Chem 265: 8304-8310.
44. Siddesha JM, Valente AJ, Sakamuri SSVP, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65: 9-18, 2013.
45. Sklan EH, Podoly E, Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol 78: 117-134, 2006.
46. Sosunov AA, Hassall CJ, Loesch A, Turmaine M, Feher E, Burnstock G. Neuropeptide Y-immunoreactive intracardiac neurones, granule-containing cells and nerves associated with ganglia and blood vessels in rat and guinea-pig heart. Cell Tissue Res 289: 445-454, 1997.
47. Tofovic DS, Bilan V, Jackson EK. Sitagliptin enhances angiotensin II-induced hypertension and cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 54: E64-E65, 2009.
48. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 93: 647-664, 2009.
49. Verrier JD, Jackson TC, Gillespie DG, Janesko-Feldman K, Bansal R, Goebbels S, Nave KA, Kochanek PM, Jackson EK. Role of CNPase in the oligodendrocytic extracellular 2=,3=-cAMP-adenosine pathway. Glia 61: 1595-1606, 2013.
50. Volpe M, McKelvie R, Drexler H. Hypertension as an underlying factor in heart failure with preserved ejection fraction. J Clin Hypertens (Greenwich) 12: 277-283, 2010.
51. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Yeh CM, Chen TJ, Lin SJ, Chiang CE. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 177: 86-90, 2014.
52. Warner MR, Senanayake PD, Ferrario CM, Levy MN. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 69: 455-465, 1991.
53. Wieland HA, Eckard CP, Doods HN, Beck-Sickinger AG. Probing of the neuropeptide Y-Y1-receptors interaction with anti-receptor antibodies. Eur J Biochem 255: 595-603, 1998.
54. Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 67: 112-125, 2014.
55. Yang T, Levy MN. Sequence of excitation as a factor in sympatheticparasympathetic interactions in the heart. Circ Res 71: 898-905, 1992.
56. Yu L, Yang G, Weng X, Liang P, Li L, Li J, Fan Z, Tian W, Wu X, Xu H, Fang M, Ji Y, Li Y, Chen Q, Xu Y. Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35: 1207- 1217, 2015.
57. 2+ signaling in cardiac fibroblasts. Arch Biochem Biophys 564: 74-82, 2014.
58. Yu Y, Chen S, Xiao C, Jia Y, Guo J, Jiang J, Liu P. TRPM7 is involved in angiotensin II induced cardiac fibrosis development by mediating calcium and magnesium influx. Cell Calcium 55: 252-260, 2014.
59. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385: 2067-2076, 2015.